Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

28 Sep 2005 07:02

Quintessentially English PLC28 September 2005 Quintessentially English PLC ('Quintessentially English' or the 'Company') Interim Results The Company announces its interim results for the six month period to 30th June2005. There was a turnover of £Nil, and a loss after tax of £56,283. No directorsreceived any remuneration during the period. No dividend is recommended. Since the Company's successful Admission to AIM in March 2004, the Company hasevaluated a number of potential investments and continues to do so. Costs include fees incurred in respect of a particular transaction which in theevent was aborted during due diligence. For further information: Quintessentially English PLCMr Michael Gurner, 07768 231 731 Profit and Loss AccountFor the period 01/01/05 to 30/06/05 Note Period Ended 30/06/2005 (unaudited) £ Turnover -Administrative expenses (60,633) ------------Operating Loss (60,633)Interest Receivable 4,382Interest Payable (32) ------------Loss on ordinary activities before taxation 1 (56,283)Taxation - ------------Loss on ordinary activities after taxation (56,283) ------------ Basic and diluted earnings per Ordinary share (pence)(0.50) ------------ Dividends per share (pence) 0 ------------ Balance Sheet As at 30/06/05 Note 30/06/2005 (unaudited) £ £ Fixed assets Investments 2 Current AssetsCash at bank and in hand 198,277Current LiabilitiesCreditors: Amounts falling due within one year (48,120) ------------Net current assets 150,157 -----------Total assets less current liabilities 150,159 ----------- Called up share capital 2 111,769Share premium 3 167,867Profit and loss account (129,477) -----------Equity shareholders funds 150,159 -----------Net assets per share (pence) 4 1.34p ----------- Cash Flow Statement For the period from 01/01/05 to 30/06/05 Note Period Ended 30/06/2005 (unaudited) £ Net cash inflow from operating activities (28,677) ----------- Returns on investment and servicing of finance:Interest received 4,382Interest payable (32) -----------Decrease in cash (24,327) ----------- Notes to the Interim Report 1. Loss on ordinary activities before taxation The loss for the period is representative of operational overheads incurred inthe period. 2. Called up share Capital The issued share capital compromises 11,176,865 ordinary shares of 1p each,consisting of 200 shares of 1p each issued as two £1 subscriber shares onincorporation and converted into 1p shares on 23rd February 2004, 6,666,665ordinary shares of 1p each issued on 24th February 2004 and 4,510,000 ordinaryshares of 1p each issued on 18th March 2004. 3. Share premium The share premium represents: £Premium arising on issues of ordinary shares in the period ended 31/12/2004 213,731Expenses of share issues in the period ending 31/12/2004 (45,864) -----------At 30th June 2005 167,867 ----------- 4. Net assets per share The calculation of net assets per share is based on the net assets at the end ofthe period of £150,159 and on the number of ordinary shares in issue(11,176,865) at 30th June 2005. 5. Preparation of Interim Report The interim financial information for the period from 1 January 2005 to 30thJune 2005 was approved by the directors on 19 September 2005. 6. Financial information The financial information in this statement does not constitute statutoryaccounts within the meaning of section 240 of the Companies Act 1985. 7. Availability Copies of the interim financial information for the period from 1 January 2005to 30th June 2005 are not being sent to shareholders. Copies will be availablefrom the Company's registered office, which is at 235 Old Marylebone Road,London NW1 50T. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
10th Apr 20187:00 amRNSStrategic Review of operations and Trading Update
12th Jan 201812:14 pmRNSHolding(s) in Company
21st Dec 20177:00 amRNSAllersys® CE-Mark
14th Dec 20177:01 amRNSCEO succession
14th Dec 20177:00 amRNSInterim results
29th Nov 20177:00 amRNSVISITECT® CD4 CE-Mark
1st Nov 20177:00 amRNSChange of Registered Office
23rd Oct 20177:00 amRNSTrading Update and Notice of Interim Results
18th Oct 20179:00 amRNSPDMR Participation in SAYE Scheme
16th Oct 20177:00 amRNSUS Supply Agreement
10th Oct 20177:00 amRNSHolding(s) in Company
5th Sep 20172:07 pmRNSExercise of Options and Total Voting Rights
29th Aug 201711:51 amRNSResult of AGM
18th Jul 201710:35 amRNSResult of General Meeting
6th Jul 201711:56 amRNSSale and leaseback of building owned by Omega GmbH
30th Jun 201712:13 pmRNSResult of Proposed Fundraising
30th Jun 20177:01 amRNSProposed Fundraising
30th Jun 20177:00 amRNSFinal Results
25th Apr 20177:00 amRNSTrading Update and Notice of Results
21st Apr 201712:41 pmRNSHolding(s) in Company
29th Mar 20177:00 amRNSVISITECT® Malaria CE-Mark & Indian FDA inspection
7th Mar 20178:45 amRNSHolding(s) in Company
27th Feb 201712:52 pmRNSHolding(s) in Company
27th Jan 20177:00 amRNSUpdate on discussions with IDS
11th Jan 20177:00 amRNSISO accreditation for manufacturing facility
29th Nov 20167:15 amRNSHardman Research: Food intolerance driving growth
24th Nov 20167:52 amRNSHolding(s) in Company
21st Nov 20167:00 amRNSHalf-year Report
31st Oct 20167:15 amRNSHardman Research: Diagnosing growth opportunities
17th Oct 20167:00 amRNSTrading Update and Notice of Interim Results
10th Aug 201612:22 pmRNSResult of AGM
2nd Aug 20167:00 amRNSR&D Grant Funding
4th Jul 20168:18 amRNSHolding(s) in Company
1st Jul 201611:48 amRNSHolding(s) in Company
27th Jun 20167:00 amRNSFinal Results
9th Jun 20169:07 amRNSHolding(s) in Company
21st Apr 20167:00 amRNSTrading Update & Notice of Results
8th Feb 20168:22 amRNSHolding(s) in Company
4th Dec 20154:25 pmRNSHolding(s) in Company
3rd Dec 201512:28 pmRNSHolding(s) in Company
30th Nov 20157:00 amRNSHalf Yearly Report
26th Oct 20157:00 amRNSTrading Update and Notice of Interim Results
30th Sep 20159:07 amRNSGrant of Options
7th Sep 20151:21 pmRNSResult of AGM
7th Jul 20157:00 amRNSFinal Results
5th Jun 201510:01 amRNSHolding(s) in Company
1st Jun 20157:00 amRNSDevelopment Update - Visitect® CD4 and Allergy
27th Apr 20157:00 amRNSBoard Appointment
15th Apr 20157:00 amRNSTrading update and Notice of Results
1st Dec 201410:37 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.